Clinical efficacy and safety of conversion from cyclosporine A to tacrolimus-based regimen for differen pathological types of chronic allograft nephropathy patients

Journal of Clinical Rehabilitative Tissue Engineering Research

Volumn 14, Issue 18, 2010, Pages 3408-3411

  Sen, Gao ^a   Yi, Gao ^a   Liu, Yong Guang ^a   Ding, Liu ^a   Ying, Guo ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JAPAN; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PROTEINURIA; STEADY STATE; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77955017879     PISSN: 16738225     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-8225.2010.18.044     Document Type: Article

References (16)

1. Zisman AL, Sprague SM. Chronic Allograft Nephropathy. Adv Chronic Kidney Dis. 2006;13(1):56-61.
2. Kosch M, Hausberg M, Suwelack B. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation. 2003;76(10):1516-1519.
3. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006;81(5):643-654.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326-2333.
5. Meier M, Nitschke M, Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation. 2006;81(7):1035-1040.
6. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol. 2003;14(11):2980-2984.
7. Banasik M, Klinger M. Chronic allograft nephropathy-immunologic and nonimmunologic factors. Ann Transplant. 2006;11(1):7-10.
8. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22(1):1-15.
9. Artz MA, Boots J, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant. 2004;4(6):937.
10. Cheung C Y, Wong KM, Chan HW, et al. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. Transplant International. 2006;19(8):657-666.
11. Waid T. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant. 2005;19(5):573-580.
12. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int. 2006;70(6):1019-1025.
13. Bing P, Maode L, Li F, et al. Expression of renal transforming growth factor-beta and its receptors in a rat model of chronic cyclosporine-induced nephropathy. Transplant Proc. 2006;38(7):2176-2179.
14. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, et al. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant. 2004;19 Suppl 3: i47-i51.
15. Krämer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant. 2005;20(5):968-973.
16. Stoves J, Newstead CG, Baczkowski AJ, et al. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Nephrol Dial Transplant. 2004;19(8):2113-2120.